NorthStar Medical Radioisotopes - About the company
NorthStar Medical Radioisotopes is a series B company based in Madison (United States), founded in 2006 by George Messina. It operates as a Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market. NorthStar Medical Radioisotopes has raised $15.1M in funding from Hendricks Holding and Stateline Angels. The company has 29 active competitors, including 6 funded and 4 that have exited. Its top competitors include companies like Curium, ARTMS and AZI.
Company Details
Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market. Its patented technologies include innovative non-uranium-based molybdenum-99 production methods, a novel separation chemistry system, and tools for the nuclear medicine market. Products include Non-HEU 99-Molybdenum and RadioGenix intelligent isotope separation system. Claims to be the first domestic producer of 99-Molybdenum and the only supplier of Non-HEU material.
Key Metrics
Founded Year
2006
Location
Madison, United States
Stage
Series B
Total Funding
$15.1M in 19 rounds
Latest Funding Round
Investors
Ranked
2nd among 29 active competitors
Employee Count
322 as on Aug 31, 2026
Sign up to download NorthStar Medical Radioisotopes' company profile
NorthStar Medical Radioisotopes's funding and investors
NorthStar Medical Radioisotopes has raised a total funding of $15.1M over 19 rounds. Its first funding round was on Mar 11, 2010. Its latest funding round was a Conventional Debt round on Oct 02, 2026 for $*****. 1 investor participated in its latest round. NorthStar Medical Radioisotopes has 6 institutional investors.
Here is the list of recent funding rounds of NorthStar Medical Radioisotopes:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 02, 2026 | 4777866 | Conventional Debt | 2406332 | 1552300 | 9080233 | 1622805 |
May 13, 2025 | 3923809 | Grant (prize money) | 2838508 | 5024315 | 6687171 | |
Jul 23, 2019 | 2127308 | Grant (prize money) | 7295133 | 4160244 | 4685176 |
Access funding benchmarks and valuations. Sign up today!View details of NorthStar Medical Radioisotopes's funding rounds and investors
NorthStar Medical Radioisotopes' founders and board of directors
Founder? Claim ProfileThe founders of NorthStar Medical Radioisotopes is George Messina.
Here are the details of NorthStar Medical Radioisotopes' key team members:
- George Messina: Co-Founder & CEO of NorthStar Medical Radioisotopes.
NorthStar Medical Radioisotopes' employee count trend
NorthStar Medical Radioisotopes has 322 employees as of Aug 26. Here is NorthStar Medical Radioisotopes's employee count trend over the years:
Uncover NorthStar Medical Radioisotopes' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
NorthStar Medical Radioisotopes's Competitors and alternates
Top competitors of NorthStar Medical Radioisotopes include Curium, ARTMS and AZI. Here is the list of Top 10 competitors of NorthStar Medical Radioisotopes, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Specialty developer, manufacturer & distributor of radiopharmaceuticals | - | 58/100 | ||
2nd | NorthStar Medical Radioisotopes 2006, Madison (United States), Series B | Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market | $15.1M | 58/100 | |
3rd | Provider and developer of radioisotope technologies | $26.6M | 46/100 | ||
4th |  AZI 2017, Bunker Hill (United States), Series C | Developer of radiopharmaceuticals for imaging purposes | $58.3M | - | 42/100 |
5th | Ground Fluor Pharmaceuticals 2012, Lincoln (United States), Series A | Biomedical company developing proprietary new chemistry for the synthesis of pharmaceutical compounds | - | 37/100 | |
6th | Am Chemicals 2003, Oceanside (United States), Unfunded | Oligonucleotide synthesis solutions: solid supports, reagents, and expert services | - | - | 33/100 |
7th |  CellBion 2010, Seoul (South Korea), Public | Radioactive probes for imaging | - | 33/100 | |
8th | Developing multimodal visualization agents | $2.3M | 32/100 | ||
9th | Custom synthesis of stable radioisotopes & analytical services for pharmaceutical and biotech companies | - | 31/100 | ||
10th | Developer of infra red fluorescence based diagnostic molecules | $724K | 30/100 |
_1523278348268.png?devicePixelRatio=2&height=30&width=30){kind=logo}
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on NorthStar Medical Radioisotopes's competitors? Click here to see the top ones
NorthStar Medical Radioisotopes's Investments and acquisitions
NorthStar Medical Radioisotopes has made no investments or acquisitions yet.
Reports related to NorthStar Medical Radioisotopes
Here is the latest report on NorthStar Medical Radioisotopes's sector:
News related to NorthStar Medical Radioisotopes
Filter this listMedia has covered NorthStar Medical Radioisotopes for a total of 11 events in the last 1 year, 4 of them have been about partnerships and 3 about people movement.
•
Low Institute for Therapeutics and NorthStar Partner to Advance Novel Radioligand Therapy for Cancer-Associated Bone DiseaseBusiness Wire•May 28, 2026•Lowinstitute, NorthStar Medical Radioisotopes
•
NorthStar and QSA Global Announce Strategic Partnership to Strengthen Actinium-225 Supply ChainCNW•May 27, 2026•NorthStar Medical Radioisotopes, QSA Global
•
NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225Business Wire•Apr 15, 2026•NorthStar Medical Radioisotopes
•
Bioemtech, Northstar Medical Radioisotopes Reach Agreement For Ac-225 SupplyContract Pharma•Feb 18, 2026•BioEmission Tech, NorthStar Medical Radioisotopes
•
Convergent Therapeutics and NorthStar Medical Radioisotopes Announce Expanded Partnership to Support Convergent's Late-Stage Alpha-Emitting Radioantibody ProgramBusiness Wire•Jan 06, 2026•NorthStar Medical Radioisotopes, Convergent Therapeutics
•
Leadership Changes at NorthStar Medical RadioisotopesContract Pharma•Dec 16, 2025•NorthStar Medical Radioisotopes
•
Kathy Spencer-Pike Joins NorthStar Medical Radioisotopes, LLC as Chief Commercial OfficerBusiness Wire•Dec 16, 2025•NorthStar Medical Radioisotopes
•
Victor Miller Joins NorthStar Medical Radioisotopes, LLC as Chief Financial OfficerBusiness Wire•Dec 16, 2025•NorthStar Medical Radioisotopes
•
Clarity signs copper-67 Supply Agreement with NusanoBenzinga•Oct 16, 2025•Nusano, NorthStar Medical Radioisotopes, Clarity Pharmaceuticals
•
NorthStar Medical Technologies Appoints Jon Coulter as Non-Executive ChairmanBusiness Wire•Aug 11, 2025•NorthStar Medical Radioisotopes
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about NorthStar Medical Radioisotopes
Explore our recently published companies
- Marketing Agency - Deptford based, 2020 founded, Unfunded company
- Aquiyel Services - Houston based, 2020 founded, Public company
- B2clogin.com - 2017 founded, Unfunded company
- Compose Finance - Warsaw based, 2024 founded, Unfunded company
- Bubbls - United Kingdom based, Unfunded company
- TedhiMedhi Family - India based, Unfunded company
